![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Former Heritage Pharmaceuticals Execs Charged in DOJ Probe of Generics Prices
Former Heritage Pharmaceuticals Execs Charged in DOJ Probe of Generics Prices
December 15, 2016
Two former Heritage Pharmaceuticals executives were accused by the Justice Department of conspiring to fix the prices of generic versions of the antibiotic doxycycline hyclate and the diabetes therapy glyburide — the first felony charges in a two-year investigation.
The company’s former CEO Jeffrey Glazer and previous president Jason Malek allegedly colluded to inflate the prices of doxycycline from April 2013 to at least Dec. 2015, and entered agreements to hike the price of glyburide from April 2014 to at least Dec. 2015. The two men are expected to plead guilty.
More than a dozen generics makers — including Mylan, Mayne, Endo, Sun Pharmaceuticals and Teva — have received subpoenas from the DOJ related to the price of their generics.
Upcoming Events
-
21Oct